Back to Browse Journals » Clinical Ophthalmology » Volume 2 » Issue 2

Current and emerging therapies for the treatment of age-related macular degeneration

Authors M Vaughn Emerson, Andreas K Lauer

Published Date June 2008 Volume 2008:2(2) Pages 377—388

DOI http://dx.doi.org/10.2147/OPTH.S1485

Published 30 June 2008

M Vaughn Emerson, Andreas K Lauer

Casey Eye Institute, Oregon Health and Science University, Portland, OR, USA

Abstract: Age-related macular degeneration (AMD) is the leading cause of vision loss in the industrialized world. In the last few decades, the mainstay of treatment for choroidal neovascularization (CNV) due to AMD has been thermal laser photocoagulation. In the last decade, photodynamic therapy with verteporfin extended treatment for more patients. While both of these treatments have prevented further vision loss in a subset of patients, improvement in visual acuity is rare. Anti-vascular endothelial growth factor A (VEGF) therapy has revolutionized the treatment of AMD-related CNV. Pegaptanib, an anti-VEGF aptamer prevents vision loss in CNV, although the performance is similar to that of photodynamic therapy. Ranibizumab, an antibody fragment and bevacizumab, a full-length humanized monoclonal antibody against VEGF have both shown promising results with improvements in visual acuity with either agent. VEGF trap, a modified soluble VEGF receptor analogue, binds VEGF more tightly than all other anti-VEGF agents and has also shown promising results in early trials. Other treatment strategies to decrease the effect of VEGF have used small interfering ribonucleic acid (RNA) to inhibit VEGF production and VEGF receptor production. Steroids, including anecortave acetate in the treatment and prevention of CNV, have shown promise in controlled trials. Receptor tyrosine kinase inhibitors, such as vatalanib, inhibit downstream effects of VEGF, and have been effective in the treatment of CNV in early studies. Squalamine lactate inhibits plasma membrane ion channels with downstream effects on VEGF, and has shown promising results with systemic administration. Other growth factors, including pigment epithelium-derived growth factor that has been administered via an adenoviral vector has shown promising initial results. In some patients ciliary neurotrophic factor is currently being studied for the inhibition of progression of geographic atrophy. Combination therapy has been investigated, and may prove to be more effective in the management of AMD-associated CNV. Ongoing and future studies will be crucial for optimizing the treatment of patients with AMD.

Keywords: age related macular degeneration, macular degeneration, VEGF, VEGF antagonist, anti-VEGF, choroidal neovascularization

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Electroretinographic findings in transplant chorioretinopathy

Brian T Chan-Kai, Steven Yeh, Richard G Weleber, et al

Clinical Ophthalmology 2010, 4:777-783

Published Date: 14 July 2010

Readers of this article also read:

Electro interstitial scan system: assessment of 10 years of research and development

Maarek A

Medical Devices: Evidence and Research 2012, 5:23-30

Published Date: 5 March 2012

Aminopropyltriethoxysilane-mediated surface functionalization of hydroxyapatite nanoparticles: synthesis, characterization, and in vitro toxicity assay

Wang S, Wen S, Shen M, Guo R, Cao X, Wang J, Shi X

International Journal of Nanomedicine 2011, 6:3449-3459

Published Date: 20 December 2011

Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer

Chauhan A, Zubair S, Tufail S, Sherwani A, Sajid M, Raman SC, Azam A, Owais M

International Journal of Nanomedicine 2011, 6:2305-2319

Published Date: 12 October 2011

Contraception usage among young adult men in a developing country

Paul A Bourne, Christopher AD Charles

Open Access Journal of Contraception 2010, 1:51-59

Published Date: 26 July 2010

Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity

Joseph Finkelstein, Eunme Cha, Steven M Scharf

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:337-349

Published Date: 4 September 2009

Etiology of hypercoagulable state in women with recurrent fetal loss without other causes of miscarriage from Southern Italy: new clinical target for antithrombotic therapy

Maristella D’Uva, Pierpaolo Di Micco, Ida Strina, Antonio Ranieri, Carlo Alviggi, et al

Biologics: Targets and Therapy 2008, 2:897-902

Published Date: 15 October 2008

Diffuse iris melanoma: Report of a case with review of the literature

Simon E Skalicky, Michael Giblin, R Max Conway

Clinical Ophthalmology 2007, 1:339-342

Published Date: 3 December 2007

Glutaric acid as a spacer facilitates improved intracellular uptake of LHRH–SPION into human breast cancer cells

Challa SSR Kumar, Carola Leuschner, Michelle Urbina, Tevhida Ozkaya, Josef Hormes

International Journal of Nanomedicine 2007, 2:175-179

Published Date: 16 August 2007